Sep 9, 2022| JD Health

JD Health’s “Pharmacy Clinic” Awarded at CIFTIS

Vivian Yang

by Vivian Yang

JD Health’s online pharmaceutical consulting service was awarded as an excellent demonstration case in China’s service industry by the committee of the China International Fair for Trade in Services (CIFTIS) on September 5^th in Beijing.

JD Health launched the service, known as the “Pharmacy Clinic,” in June 2022. The service connects licensed pharmacists with clinic experiences to patients through the internet. Based on each patient’s condition, pharmacists provide medicine evaluation and customized adjustment plans, follow up with their medicine use, offer pharmaceutical advice and more, hence providing patients with a one-stop medication service solution outside of offline doctor’s visits.

The National Medical Products Administration issued supervision and management measures on online sales of medicines on the same day, September 5, which stated specific requirements on ensuring the safety of online medicine sales, among which Article 10 clearly says that enterprises engaged in online sales of medicines shall establish a pharmaceutical care system, and carry out prescription examination and guidance on rational use of medicines and other services from certified pharmacists and other pharmaceutical technicians to consumers. JD Health’s “Pharmacy Clinic” has undoubtedly taken action a step ahead of the new rules from the government.

Currently, more than 2,000 certified pharmacists are providing online pharmaceutical consulting services on JD Health. Such service will continue to be integrated with JD Health’s other online services including its internet hospitals, JD Pharmacy’s single-disease care centers and more, building a better user experience in post-diagnosis medicine use management and home-based pharmaceutical services.

(vivian.yang@jd.com)

Dec 25, 2024| JD Health, JD Retail

JD Report: Five Health Consumption Trends for 2024

Vivian Yang

On December 24th, JD.com’s Consumption and Industry Development Research Institute, in collaboration with HealthInsight, a media think tank specializing in the health sector, released an insightful analysis of China’s 2024 health consumption landscape. The report outlines five key trends in the health industry, highlighting the increasing consumer demand for proactive health management and the industry’s evolving dynamics.

The Rise of Weight Management Solutions

Modern lifestyles have contributed to rising obesity rates with 34.3% of Chinese adults classified as overweight and 16.4% as obese. Obesity is associated with over 200 diseases, posing significant health risks. The introduction of semaglutide, a GLP-1 receptor agonist for long-term weight management, in China marks a promising development. The market for GLP-1 weight loss drugs in China is projected to exceed 37.852 billion RMB by 2030. On JD.com, searches related to “weight management” have increased more than 3.8 times year-on-year, with growing demand for diet products and home fitness equipment such as kettlebells and leg trainers.

Addressing the Growing Mental Health Concerns
With 95 million people in China affected by depression, mental health is an increasing concern. Consumers are turning to books, stress-relief toys, online consultations, and meditation to manage stress. On JD.com, searches for “mental health” have doubled, with significant interest in emotional release tools and psychological books. JD Health’s Internet Hospital now offers specialized clinics with over 2,300 counselors addressing issues like anxiety, depression, and sleep disorders.

The Booming Sleep Economy
Over 300 million Chinese experience sleep disorders, often due to irregular schedules. The sleep economy is booming with the market size reaching 495.58 billion RMB in 2023 and expected to surpass 600 billion RMB by 2027. JD.com has seen a 210% increase in searches for sleep aids, with high demand for sleep headphones, eye masks, and nutritional supplements. Sales of sleep-enhancing pillows and mattresses have also grown significantly.

Everyday Integration of Medical Devices

The home medical device market is expanding as consumers increasingly monitor their health independently. Products like heart rate-monitoring smartwatches and glucose meters are becoming household staples. This year, JD.com data shows that purchases of vision care devices and smart health monitoring equipment have tripled. The market for home medical devices is expected to reach 380 billion RMB by 2025.

Shifting Focus to Preventive Health Management

Emphasizing early screening and intervention, JD.com has seen a significant rise in orders for health services such as genetic testing and early cancer screening. These trends highlight a shift from treatment to prevention, driven by technological advancements and policy support. As consumer awareness grows, health consumption is becoming a major force in economic development, presenting opportunities for rapid growth in the health industry.

In conclusion, the 2024 health consumption landscape is characterized by a strong shift towards proactive health management and the integration of technology into everyday health practices. These trends not only reflect changing consumer priorities but also indicate significant growth opportunities for businesses in the health sector. JD.com remains committed to supporting these developments by providing innovative products and services tailored to the evolving needs of consumers across the dynamic health sector.

(vivian.yang@jd.com)

Dec 12, 2024| Global Partners/ Brands, JD Health

JD Health Debuts Merck’s New Diabetes Medication GLUCOPHAGE® XR (Reduce Mass) Online in China

Vivian Yang

On December 10, JD Health, in collaboration with Merck, a globally renowned biopharmaceutical leader, began offering GLUCOPHAGE® XR (Reduce Mass), the metformin hydrochloride extended-release tablets, and became the first online pharmacy in China to provide the new antidiabetic medication developed by Merck. This launch signifies a major milestone in the partnership between JD Health and Merck, which is dedicated to enhancing the online availability and accessibility of innovative treatments for type 2 diabetes patients in China, thereby offering them a more convenient and effective medication experience.

GLUCOPHAGE® has been a cornerstone in the treatment of type 2 diabetes for over 60 years worldwide. The latest version of this medication is designed to enhance patient adherence by reducing the long-term burden of medication administration while maintaining its therapeutic benefits. The use of GSD sustained-release technology extends the time the medication remains in the stomach, reduces gastrointestinal irritation, and improves drug absorption. Additionally, the tablet is now smaller, has reduced volume by 30%, and has been transitioned from a capsule to a round shape, making it easier to swallow. It requires only once-daily administration, significantly enhancing patient convenience and safety.

To celebrate the online launch collaboration, JD Health and Merck hosted a special release event for the new medication at the 7th China International Import Expo in November. This event followed their partnership agreement in September, which also marked the opening of Merck China’s self-operated flagship store on JD.com.

With a large user base, robust supply chain, and rich medical service resources, JD Health has become a preferred partner to launch many chronic disease medications online. By seamlessly integrating online and offline resources, JD Health ensures that new drug information reaches the right users swiftly, offering convenient purchasing options and improving drug accessibility and usage efficiency. Additionally, JD Health’s extensive logistics network ensures timely and secure delivery of medications, enhancing user experience and building trust.

(vivian.yang@jd.com)

JD Cloud Aims to Accelerate Industrial AI